Why the study?
Antiarrhythmic drug therapy and catheter ablation for ventricular tachycardia from myocardial scarring have limited efficacy and potential adverse effects, prompting evaluation of stereotactic body radiotherapy.
Does stereotactic body radiotherapy (SBRT) improve outcomes in patients with ventricular tachycardia refractory to antiarrhythmic drugs and catheter ablation?
Does stereotactic body radiotherapy (SBRT) improve outcomes in patients with ventricular tachycardia refractory to antiarrhythmic drugs and catheter ablation?
Stereotactic body radiotherapy is an emerging non-invasive treatment modality for ventricular tachycardia refractory to standard therapies.
Answers are grounded in this paper and cite their sources.
SBRT may be feasible for refractory VT in select cases; hypothesis-generating and requires prospective trials before any practice change.
Ventricular tachycardia (VT) caused by myocardial scaring bears a significant risk of mortality and morbidity. Antiarrhythmic drug therapy (AAD) and catheter ablation remain the cornerstone of VT management, but both treatments have limited efficacy and potential adverse effects. Stereotactic body radiotherapy (SBRT) is routinely used in oncology to treat non-invasively solid tumors with high precision and efficacy. Recently, this technology has been evaluated for the treatment of VT. This review presents the basic underlying principles, proof of concept, and main results of trials and case series that used SBRT for the treatment of VT refractory to AAD and catheter ablation.
No takes yet. Share an insight, caveat, or question.
Jumeau et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: